BCDA · BioCardia, Inc.

BioCardia reported a net loss of $2.3 million for Q1 2026, improving from a $2.7 million loss in the same period last year. The reduction was driven by lower research and development expenses ($1.2 million vs. $1.5 million) due to the closeout of the CardiAMP HF trial, partially offset by early enrollment in the CardiAMP HF II trial and regulatory activities in Japan. Selling, general and administrative expenses also decreased to $1.0 million from $1.2 million, primarily due to lower professional service fees. The company ended the quarter with $951,000 in cash and cash equivalents, down from $2.5 million at year-end 2025, reflecting net cash used in operations of $1.7 million. On the regulatory front, BioCardia achieved significant milestones: Japan's PMDA determined that clinical safety and efficacy evidence for CardiAMP cell therapy in ischemic heart failure is likely sufficient to support market clearance, with a Shonin submission expected in Q4 2026. The FDA also agreed that Premarket Approval (PMA) is the appropriate pathway and recommended continuing the confirmatory CardiAMP HF II trial. Additionally, the Helix biotherapeutic delivery system received FDA guidance on two potential clearance pathways. Management highlighted the progress in advancing CardiAMP toward initial regulatory approval in Japan, where an estimated 20,000 patients annually could be treated. The company also noted that primary results of the CardiAMP chronic myocardial ischemia cohort have been accepted for oral presentation at Euro PCR in May 2026. Despite the low cash position, the regulatory advancements and potential near-term catalysts in Japan and the U.S. underscore the high materiality of this filing.